Skip to main content

LKFT · Lakefront Biotherapeutics NV

Track LKFT — free
$33.47 +0.08 (+0.24%)
Market Cap
$2.20B
Shares
65.90M
Volume · Nov 20 33.9K Avg daily vol (3M) 281.53K

Price & Indicators

 

Key stats

Close
$33.39
Thu 19 Nov
Open
$33.70
Thu 19 Nov
Average volume, 30 days
254K
shares a session
Short interest
1.3M
2.0% of shares · 6.0 days to cover
Day range
$33.32$34.12
Open $33.70 Close $33.39
52-week closing range
$26.08$34.79
Close $33.39 4.0% under the high
Short volume, last session
85%
Last earnings
Nov 11, 2026
Price history
Jan 2020 to Nov 2026

Up next

Feb 24, 2027 Scheduled · in 14 wks

Latest documents

2026
Nov 18
Current report 6-K
Board creates 150,000 employee subscription rights under new plan

The Board created 150,000 subscription rights under a new plan on November 10, 2026, to compensate current and future employees. Each right allows subscribing to one new share.

3 source passages
On November 10, 2026, the Board of Directors of Lakefront approved the “Subscription Right Plan November 2026”, intended for personnel of the Company and its subsidiaries, within the framework of the authorized capital. Under this subscription right plan, 150,000 subscription rights were created for compensation of current and potential future employees. Each subscription right gives the right to subscribe to one new Lakefront share. Open the document at this passage
Nov 17
Investor event
Gamgertamig Registrational Studies Could Start as Early as 2027

Lakefront says it is preparing registrational studies of Gamgertamig in ITP and WAIHA, possibly starting in 2027, and holds 2.2 billion euros in cash.

2 source passages
You've indicated that registrational development could begin as early as 2027 in both ITP and WAIHA. we're certainly in a unique position as a biotech with presently 2.2 billion euros of cash on the balance sheet. Open the document at this passage
Nov 16
Current report 6-K
€50 million share repurchase program initiated

Lakefront Biotherapeutics NV initiated a share repurchase program of up to €50 million, covering up to 4,604,550 ordinary shares, beginning November 16, 2026 and ending on the earlier of March 31, 2027 or mandate completion.

3 source passages
Mechelen, Belgium; November 16, 2026; 7.30 AM CET regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced the initiation of a new share repurchase program of up to €50 million, following completion of its initial €50 million program announced on June 9, 2026. In accordance with the limits of the repurchase authorization granted, under the program, the Company may repurchase up to 4,604,550 ordinary shares for an aggregate amount of up to €50 million. The program will commence on November 16, 2026, and will end on the earlier of March 31, 2027, or completion of the mandate. Open the document at this passage
Nov 12
Current report 6-K
€13.9 million profit and €2.0 to €2.05 billion cash guidance

Lakefront reported €13.9 million net profit for the first nine months of 2026 and expects year-end 2026 cash and financial investments of €2.0 to €2.05 billion, including a second €50 million share repurchase program.

3 source passages
Lakefront reported a net profit of €13.9 million for the first nine months of 2026, compared to a net loss of €461.3 million for the first nine months of 2025. The Company expects its year-end 2026 cash and financial investments balance to be in the range of €2.0 to €2.05 billion. The Board of Directors of Lakefront has approved a second €50 million share repurchase program. Open the document at this passage
Nov 12
Current report 6-K
Fireside chat set for Jefferies Global Healthcare Conference

Lakefront Biotherapeutics NV will host a fireside chat at the 2026 Jefferies Global Healthcare Conference in London at 2:00 pm GMT (9:00 am ET) on Tuesday, November 17, 2026.

Source passage
Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the Company will host a fireside chat at the 2026 Jefferies Global Healthcare Conference in London at 2:00 pm GMT (9:00 am ET) on Tuesday, November 17, 2026. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+9.5%
Trailing year
Short interest
2.0%
Latest settlement · 6.0 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Bullish Fundamentals Limited Quant / Vol Moderate
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +12%
above
Price vs 50-day avg +8%
above
RSI (14) 58
neutral
MACD trend Negative
52-week position 84%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +6%
trailing
6-month return +21%
trailing
YTD return +2%
this year
Relative strength +27%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $31 › 200d $30 — 50d above 200d
Institutional flow Accumulating
+22% holders QoQ · +22 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.97% of shares out · ▼ -8.2% MoM · 6.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
95 holders — near 3-yr high, broad support
Squeeze score 53
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Moderate
Volatility 28%
annualized · 1-yr
Max drawdown −25%
past year
ATR 2.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Dec 31, 2020
Jyseleca contribution margin · second half of this decade 50%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+12% Bullish
Price vs 50-day avg
+8% Bullish
RSI (14)
58 Neutral
MACD trend
Negative Bearish
52-week position
84% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $31 › 200d $30 — 50d above 200d
Institutional flow Accumulating
+22% holders QoQ · +22 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.97% of shares out · ▼ -8.2% MoM · 6.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
95 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $26 Now $33 · 84% Range high $35
vs 200-day avg +12% vs 50-day avg +8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
LKFT
Lakefront Biotherapeutics NV
this stock
$2.20B +2.1% — — 2.0%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
95
% held
50.9%
Net QoQ
+1.5M sh
Top holder
GILEAD SCIENCES, INC.
Held Float
View
Held by Funds
Fund positions
17
View
Short & Settlement
Short Interest Falling
Shares short
1.3M
Days to cover
6.0d
Change
-116.8K sh
View
Short Volume
Short vol %
85%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
3.5K
Value
$111.2K
As of
Oct 26, 2026
View
Off-Exchange
Off-exchange %
34.2%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Buybacks
Authorized
EUR 50.0M
View
Filings
SEC Filings
Latest
6-K
Filed
Nov 18, 2026
This year
57

The Board created 150,000 subscription rights under a new plan on November 10, 2026, to compensate current and future employees. Each right allows subscribing to one new share.

View
Earnings & Events
Webcasts Upcoming
Next webcast
Feb 24, 2027
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
Lakefront Biotherapeutics Reports…
Published
Nov 11, 2026
Upcoming events
8
View

Performance

5D 20D 120D MTD YTD
LKFT -1.6% +6.3% +21.2% +3.4% +2.1%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +3.9% +12.6% +26.9% +8.7% -2.9%

Capital returns

Buyback program · as of Nov 11, 2026
Authorized
EUR 50.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1421876 CUSIP 36315X101 13F (30d) 109 filings 93 filers Visit website Investor relations